Neurogene (NGNE) Cash from Financing Activities (2013 - 2026)
Neurogene (NGNE) posted Cash from Financing Activities of $195000.0 for Q1 2026, down 99.06% on a QoQ basis from $20.7 million in Q4 2025, and up 4775.0% year-over-year from $4000.0 in Q1 2025.
Neurogene (NGNE) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Neurogene's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $195000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 4775.0% year-over-year to $195000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.6 million (down 83.94% YoY) and the FY2025 annual result came in at $30.4 million, down 83.47% from the prior year.
- Cash from Financing Activities was $195000.0 for Q1 2026 at Neurogene, down from $20.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $190.1 million in Q4 2024 and bottomed at -$6.5 million in Q1 2024.
- A 5-year average of $22.0 million and a median of $131000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 61944.86% — and 2024, when it tumbled 6197.2%.
- Neurogene's Cash from Financing Activities stood at $66.4 million in 2022, then surged by 42.04% to $94.3 million in 2023, then surged by 101.56% to $190.1 million in 2024, then tumbled by 89.13% to $20.7 million in 2025, then sank by 99.06% to $195000.0 in 2026.
- Business Quant data shows NGNE's Cash from Financing Activities at $195000.0 in Q1 2026, $20.7 million in Q4 2025, and $9.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | 195,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 195,000.00 |
| Mar 31, 2026 | 195,000.00 |
| Dec 31, 2025 | 20.66 Mn |
| Dec 31, 2025 | 20.66 Mn |
| Sep 30, 2025 | 9.71 Mn |
| Sep 30, 2025 | 9.71 Mn |
| Jun 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 54,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 190.07 Mn |
| Dec 31, 2024 | 190.07 Mn |
| Sep 30, 2024 | 131,000.00 |
| Sep 30, 2024 | 131,000.00 |
| Jun 30, 2024 | 399,000.00 |
| Jun 30, 2024 | 399,000.00 |
| Mar 31, 2024 | -6.52 Mn |
| Mar 31, 2024 | -6.52 Mn |
| Dec 31, 2023 | 94.30 Mn |
| Dec 31, 2023 | 94.30 Mn |